期刊
BRITISH JOURNAL OF CANCER
卷 122, 期 5, 页码 601-602出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/s41416-019-0678-0
关键词
-
类别
资金
- Imperial BRC
- ECMC
- EPSRC [EP/I001700/1] Funding Source: UKRI
For many tumours there is a lack of randomised data from which we can guide systemic treatments. Although gene expression profiling along with proteomics has led to advances in diagnosis, classification and prognosis, our ability to target many cancers has been further limited due to a lack of therapeutic options. The use of patient-derived xenograft (PDX) models in the setting of a rare malignancy is discussed here by Kamili et al, with the successful establishment of new model systems.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据